-
Je něco špatně v tomto záznamu ?
Mechanistic insights into antitumor effects of new dinuclear cis Pt(II) complexes containing aromatic linkers
L. Zerzankova, H. Kostrhunova, M. Vojtiskova, O. Novakova, T. Suchankova, M. Lin, Z. Guo, J. Kasparkova, V. Brabec
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem
- MeSH
- adukty DNA chemie metabolismus MeSH
- cisplatina chemie metabolismus farmakologie MeSH
- HeLa buňky MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- poškození DNA účinky léků fyziologie MeSH
- protinádorové látky chemie metabolismus farmakologie MeSH
- reagencia zkříženě vázaná chemie metabolismus farmakologie MeSH
- viabilita buněk účinky léků fyziologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
The primary objective was to understand more deeply the molecular mechanism underlying different antitumor effects of dinuclear Pt(II) complexes containing aromatic linkers of different length, {[cis-Pt(NH(3))(2)Cl](2)(4,4'-methylenedianiline)}(2+) (1) and {[cis-Pt(NH(3))(2)Cl](2)(alpha,alpha'-diamino-p-xylene)}(2+) (2). These complexes belong to a new generation of promising polynuclear platinum drugs resistant to decomposition by sulfur nucleophiles which hampers clinical use of bifunctional polynuclear trans Pt(II) complexes hitherto tested. Results obtained with the aid of methods of molecular biophysics and pharmacology reveal differences and new details of DNA modifications by 1 and 2 and recognition of these modifications by cellular components. The results indicate that the unique properties of DNA interstrand cross-links of this class of polynuclear platinum complexes and recognition of these cross-links may play a prevalent role in antitumor effects of these metallodrugs. Moreover, the results show for the first time a strong specific recognition and binding of high-mobility-group-domain proteins, which are known to modulate antitumor effects of clinically used platinum drugs, to DNA modified by a polynuclear platinum complex.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12025087
- 003
- CZ-PrNML
- 005
- 20130226203424.0
- 007
- ta
- 008
- 120816e20100424enk f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bcp.2010.04.013 $2 doi
- 035 __
- $a (PubMed)20399754
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Marková, Lenka. $7 xx0308463 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, v.v.i., Kralovopolska 135, CZ-61265 Brno, Czech Republic.
- 245 10
- $a Mechanistic insights into antitumor effects of new dinuclear cis Pt(II) complexes containing aromatic linkers / $c L. Zerzankova, H. Kostrhunova, M. Vojtiskova, O. Novakova, T. Suchankova, M. Lin, Z. Guo, J. Kasparkova, V. Brabec
- 520 9_
- $a The primary objective was to understand more deeply the molecular mechanism underlying different antitumor effects of dinuclear Pt(II) complexes containing aromatic linkers of different length, {[cis-Pt(NH(3))(2)Cl](2)(4,4'-methylenedianiline)}(2+) (1) and {[cis-Pt(NH(3))(2)Cl](2)(alpha,alpha'-diamino-p-xylene)}(2+) (2). These complexes belong to a new generation of promising polynuclear platinum drugs resistant to decomposition by sulfur nucleophiles which hampers clinical use of bifunctional polynuclear trans Pt(II) complexes hitherto tested. Results obtained with the aid of methods of molecular biophysics and pharmacology reveal differences and new details of DNA modifications by 1 and 2 and recognition of these modifications by cellular components. The results indicate that the unique properties of DNA interstrand cross-links of this class of polynuclear platinum complexes and recognition of these cross-links may play a prevalent role in antitumor effects of these metallodrugs. Moreover, the results show for the first time a strong specific recognition and binding of high-mobility-group-domain proteins, which are known to modulate antitumor effects of clinically used platinum drugs, to DNA modified by a polynuclear platinum complex.
- 650 _2
- $a protinádorové látky $x chemie $x metabolismus $x farmakologie $7 D000970
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a viabilita buněk $x účinky léků $x fyziologie $7 D002470
- 650 _2
- $a cisplatina $x chemie $x metabolismus $x farmakologie $7 D002945
- 650 _2
- $a reagencia zkříženě vázaná $x chemie $x metabolismus $x farmakologie $7 D003432
- 650 _2
- $a adukty DNA $x chemie $x metabolismus $7 D018736
- 650 _2
- $a poškození DNA $x účinky léků $x fyziologie $7 D004249
- 650 _2
- $a HeLa buňky $7 D006367
- 650 _2
- $a lidé $7 D006801
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1#
- $a Kostrhunová, Hana. $7 _AN047101
- 700 1_
- $a Vojtíšková, Marie, $d 1946- $7 ola2003204932
- 700 1_
- $a Nováková, Olga, $d 1966- $7 xx0072650
- 700 1_
- $a Suchánková, Tereza, $d 1983- $7 mub2011617906
- 700 1_
- $a Lin, Miaoxin
- 700 1_
- $a Guo, Zijian
- 700 1_
- $a Kašpárková, Jana, $d 1969- $7 xx0068609
- 700 1_
- $a Brabec, Viktor, $d 1944- $7 jo20010087133
- 773 0_
- $w MED00000704 $t Biochemical pharmacology $x 1873-2968 $g Roč. 80, č. 3 (20100424), s. 344-351
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20399754 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120816 $b ABA008
- 991 __
- $a 20130226203640 $b ABA008
- 999 __
- $a ok $b bmc $g 947129 $s 782433
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 80 $c 3 $d 344-351 $e 20100424 $i 1873-2968 $m Biochemical pharmacology $n Biochem Pharmacol $x MED00000704
- LZP __
- $a Pubmed-20120816/10/02
